Efficacy of Carbetocin Versus Oxytocin Plus Misoprostol in Decreasing Blood Loss During Cesarean Section
Blood Loss, Surgical, Intrapartum Hemorrhage
About this trial
This is an interventional prevention trial for Blood Loss, Surgical focused on measuring estimated blood loss, carbetocin, oxytocin, misoprostol
Eligibility Criteria
Inclusion Criteria: Pregnant women planning to deliver by CS. Age between 18-40. Gestational age: (36-42 weeks). Exclusion Criteria: Women in active labour. Rupture of membranes more than 24 hours &/or intraamniotic infection. Suspected extensive adhesions eg: more than P3CS, endometriosis, previous pelvic surgery. Antepartum hemorrhage and abnormal placentation e.g.: low lying placenta, placenta previa, placenta accreta. Major intrapartum hemorrhage more than 1000 ml. History of postpartum hemorrhage. Anemia (Hb level less than 10g/dl). Uterine overdistention eg: polyhydramnios, macrosomic baby, multiple pregnancy. Known allergy to any of misoprostol, oxytocin, carbetocin. Known medical disorders: Diabetes Mellitus, hypertensive disorders, Systemic Lupus Erythematosus. Known coagulopathy problem. Contraindication &/or refusal to spinal anesthesia.
Sites / Locations
- Ain Shams Maternity Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Oxytocin+Misoprostol
Carbetocin
Patients in this group will receive 600 micrograms misoprostol rectally immediately before sterilization plus 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution immediately after delivery of the fetus.
Patients in this group will receive 100ug Carbetocin by slow IV infusion (over one minute) intra-operative immediately after delivery of the fetus.